Central nervous system invasive fungal disease in patients with B-cell malignancies treated with zanubrutinib: 3 cases report and literature review

VernacularTitle:泽布替尼治疗B细胞肿瘤患者中枢神经系统侵袭性真菌病3例报告并文献复习
Author: Zhenshuo JIN ¹ ; Yuehua HUANG ; Fan YU ; Yi GUO ; Sheng DONG ; Lihong LI ; Yanying WANG
Author Information

1. 清华大学附属北京清华长庚医院血液内科，清华大学临床医学院，北京　102218
Publication Type:Journal Article
From: Chinese Journal of Hematology 2025;46(6):575-578
CountryChina
Language:Chinese
Abstract: The advent of bruton tyrosine kinase inhibitors (BTKi) has offered more therapeutic choices for patients with B-cell malignancies. However, with its widespread application in recent years, the use of BTKi increases the risk of severe infections in patients. Here, we report three cases of B-cell malignancies, including one case of chronic lymphocytic leukemia and two cases of diffuse large B-cell lymphoma. During treatment with BTKi zanubrutinib, different degrees of invasive fungal disease (IFD) of the central nervous system occurred in these patients. All patients fully recovered following antifungal therapy. With a median follow-up of 35 months, all patients remained in a continuous remission state, and none of them had a recurrence of IFD.